Dishman Carbogen Amcis Ltd.

₹150.35

-7.1 (-4.5%)

DCAL Share Price

Pharmaceuticals & Biotechnology

As on October 1, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 2,363.51 Cr

P/E Ratio24.19

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	160.33	Bearish
10-DMA	165.41	Bearish
20-DMA	167.18	Bearish
50-DMA	176.58	Bearish
100-DMA	181.96	Bearish
200-DMA	190.07	Bearish

Historical Performance

1 Year

-45.6%

3 Years

-7.5%

5 Years

-28.8%

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	29,319	27,115	26,158	24,129	21,407
Total Expenditure	23,663	22,718	23,519	20,807	18,150
Other Income	559	509	508	278	491
Operating Profit	6,216	4,906	3,147	3,600	3,748
Interest	1,742	1,595	1,200	857	568
Depreciation	3,387	2,937	3,109	2,807	3,076
Profit Before Tax	1,049	193	-1,223	-546	-42
Consolidated Net Profit	974	32	-1,534	-298	180
Adjusted EPS	6	---	-10	-2	1

Compounded Sales Growth

10 Years:11.3

5 Years:8.9

3 Years:4

TTM:1.6

Compounded Profit Growth

10 Years:-9.5

5 Years:-27.2

3 Years:2.5

TTM:97.5

Stock Price CAGR

10 Years:N/A

5 Years:-6.6

3 Years:-2.7

TTM:-47.1

Return on Equity

10 Years:0

5 Years:1.1

3 Years:-9.8

last year:6.2

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	314	314	314	314	314
Total Reserves	66,455	58,002	55,961	57,783	55,176
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	28,460	22,300	13,884	18,314	16,655
Other Current Liabilities	11,661	9,932	6,395	8,416	7,024
Short Term Borrowings	8,367	6,553	16,202	6,808	4,926
Total Liabilities	1,18,400	99,863	95,706	94,395	86,342
Capital Work in Progress	2,750	2,517	5,008	9,963	7,548
Long Term Loans & Advances	2,746	1,905	1,928	2,172	2,108
Currents Investments	162	254	233	1,770	2,925
Short Term Loans and Advances	1,104	802	790	1,210	1,895
Total Current Assets	28,421	22,004	19,282	19,184	18,387
Total Assets	1,18,400	99,863	95,706	94,395	86,342
Adjusted Book Value	426	372	359	371	354

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 24.19, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -2.7%, indicating poor shareholder returns.
The stock carries a high beta of 1.9, implying higher volatility and elevated risk.
In the last financial year, the company reported an EBITDA of ₹6216 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹29319 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 529308.2

No. of Shares: 3521 (Approx)

Performance:-47.1%

-470691.8

NIFTY Performance: -9.9%

1 day Top Gainers